Hematopoietic cell transplantation for chronic myeloid leukemia in developing countries: Perspectives from Latin America in the post-tyrosine kinase inhibitor era

Hematology

Volumn 17, Issue SUPPL. 1, 2012, Pages

  Pasquini, Marcelo C ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

CML; Latin America; Transplant

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ALLOTRANSPLANTATION; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DEVELOPING COUNTRY; DONOR; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE PRACTICE; HEALTH CARE SYSTEM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MEDICAL EDUCATION; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; SOUTH AND CENTRAL AMERICA;

ADULT; ANTINEOPLASTIC AGENTS; DEVELOPING COUNTRIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LATIN AMERICA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84859747161     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453312X13336169155853     Document Type: Article

References (10)

1. Pasquini R, Cortes JE, Kantarjian HM, Joske D, Meillon LA, Zernovak O, et al. Survey of the frontline treatment and management of chronic myeloid leukemia (CML) in a realword setting: the 3rd annual update of the worldwide observational registry collecting longitudinal data on management of chronic myeloid leukemia patients (The WORLD CML Registry). Blood (ASH Annual Meeting Abstracts). 2011;118(21):Abstract 1695.
2. Mahon F-X, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029-35.
3. Pasquini MC, Wang Z, Horowitz M, Gale RP. 2010 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplant for blood and bone marrow disorders. In: Cecka JM, Terazaki PI, editors. Clinical transplants 2010. Los Angeles (CA): The Terasaki Foundation Laboratory; 2011. p. 87-105.
4. Khoury HJ, Kukreja M, Goldman JM, Wang T, Halter J, Arora M, et al. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transplant. 2011.
5. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260-70.
6. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251-9.
7. Cortes J, De Souza C, Ayala-Sanchez M, Bendit I, Best-Aguilera C, Enrico A, et al. Current patient management of chronic myeloid leukemia in Latin America: a study by the Latin American Leukemia Net (LALNET). Cancer. 2011;116(21):4991-5000.
8. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(6):1809-20.
9. Ruiz-Arguelles GJ, Tarin-Arzaga LC, Gonzalez-Carrillo ML, Gutierrez-Riveroll KI, Rangel-Malo R, Gutierrez-Aguirre CH, et al. Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs? Bone Marrow Transplant. 2008;42(1):23-8.
10. Bittencourt H, Funke V, Fogliatto L, Magalhaes S, Setubal D, Paz A, et al. Imatinibmesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase. Bone Marrow Transplant. 2008;42(9):597-600.